ROIV — Roivant Sciences Ltd

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Roivant Sciences Ltd

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelina… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$29.58
Market Cap$22.41B
Float531.7M
Shares Outstanding719.3M
Price/Sales (TTM)2,713.37
vs. Analyst Target+22.1% to analyst PT
Operating Margin (TTM)-14087.10%
Revenue (TTM)$8.3M
Earnings Growth (YoY)-96.10%
Dividend RateNone
Analyst Target Price$36.13 (10 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2021 $23.8M -$809M $21.7M -$721M
2022 $55.3M -$845M $46.3M -$911M
2023 $61.3M -$1.01B $48.2M -$1.18B
2024 $32.7M $4.35B $31.1M -$803M
2025 $29.1M -$172M $28.1M -$1.10B
2026 $8.3M -$300M $7.0M -$515M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 $2.2M -$223M
Sep 2025 $1.6M -$114M
Dec 2025 $2.0M -$266M
Mar 2026 $2.5M $303M

Ownership & Float

Insider Ownership22.8%
Institutional Ownership76.2%
Short Float5.1%
% of All Funds Holding5.00%
Number of Funds Holding411

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$28.55Near-term / short-term trend
Weekly40-Week SMA$22.90Medium-term trend
Weekly80-Week SMA$17.03Cyclical trend (business cycle)
Weekly200-Week SMA$12.41Secular trend (multi-year)
Monthly10-Month SMA$22.59Near-term monthly trend
Monthly20-Month SMA$16.96Medium-term monthly trend
Monthly40-Month SMA$13.64Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$15.20 support 1.37x 6 months ago
$12.00 support 1.65x 7 months ago
$10.10 support 1.37x 12 months ago

Historical Earnings Reactions (23 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -0.19% 0.00% 43.48% 4.08% -11.19%
1 Day -0.85% -0.29% 43.48% 7.16% -11.19%
1 Week -0.81% -0.81% 40.91% 12.02% -14.12%
2 Weeks -0.26% 2.39% 68.18% 15.89% -36.74%
1 Month 3.69% 1.48% 63.64% 35.52% -31.93%

Next earnings: June 4, 2026 (7 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday -0.32% 46.5% 254
Tuesday 0.28% 52.1% 284
Wednesday 0.44% 47.9% 282
Thursday -0.06% 42.2% 275
Friday 0.31% 48.7% 275

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 76.2%

Insider Transactions — Smart Summary

Total insider ownership: 22.8%

12-Month Insider Activity Summary

Total Filings41
Net Value-$232M
Net Shares Change-18,319,084
% of Float-3.4%
C-Suite Filings25
Clusters Detected6

Key Insiders

NameTitleNet ValueFilingsActivity
Gline Matthew CEO -$45.3M 3 1 buy, 2 sell
Sukhatme Mayukh President and CIO -$37.9M 2 2 sell
Pulik Richard CFO -$8.1M 1 1 sell
Venker Eric President and Immunovant CEO -$4.5M 1 1 sell
Fitzgerald Meghan -$1.3M 1 1 sell
Epperly Melissa B, -$1.2M 1 1 sell
Humes Jennifer Chief Accounting Officer -$384,073.06 1 1 sell

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-11-07 – 2025-11-21 5 5 -$120M 1 C-suite
2025-12-11 – 2025-12-19 7 7 -$226M 3 C-suite
2025-12-29 – 2025-12-31 3 3 -$41.5M 3 C-suite
2026-02-11 – 2026-02-23 6 6 -$182M 3 C-suite
2026-03-18 – 2026-03-30 3 3 -$7.4M 1 C-suite
2026-04-10 – 2026-04-22 3 3 -$14.0M 3 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-04-10 Humes Jennifer Chief Accounting Officer -$384,073.06 Transaction at $28.37, now +4.3%
2026-03-18 Epperly Melissa B, -$1.2M Transaction at $28.68, now +3.1%
2026-04-20 Gline Matthew CEO -$8.4M Transaction at $29.16, now +1.4%
2026-03-30 Fitzgerald Meghan -$1.3M Transaction at $18.12, now +63.2%
2025-12-29 Pulik Richard CFO -$8.1M Transaction at $13.14, now +125.1%
2025-12-29 Venker Eric President and Immunovant CEO -$4.5M Transaction at $13.16, now +124.8%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Roivant Sciences Ltd (ROIV) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for ROIV on Trend Edge →